Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Aug 17, 2015
Clinical News

Nuedexta dextromethorphan/quinidine: Phase IV data

BioCentury | Dec 15, 2014
Finance

Avanir Chronicles

BioCentury | Dec 8, 2014
Company News

Avanir, Otsuka Pharmaceutical deal

BioCentury | Dec 3, 2014
Top Story

Otsuka buying Avanir for $3.5B

BioCentury | Oct 6, 2014
Finance

3Q14 Stock Wrap-Up: Going big again

Winners, losers in biotech stock tiers in 3Q14
BioCentury | Sep 25, 2014
Financial News

Avanir raises $200.2M follow-on

BioCentury | Sep 22, 2014
Clinical News

Nuedexta dextromethorphan/quinidine: Phase II data

BioCentury | Sep 16, 2014
Top Story

Avanir surges on AD agitation data

Items per page:
1 - 10 of 43